5 Reasons Eli Lilly Is a Better Stock to Buy Right Now Than SpaceX

The article contrasts SpaceX’s IPO surge (trading near $150 after a nearly 20% first-day jump at a $135 IPO price) with Eli Lilly’s weight-loss drug momentum, highlighting that Mounjaro and Zepbound generated $12B+ in the latest quarter. It argues Lilly offers a more proven growth/ profitability path, citing >60% U.S. GLP-1 share, 33x forward earnings (down from >40x earlier this year), and a $6.92 dividend (~0.5% yield). Overall, it frames Lilly as a lower-risk, more steady long-term alternative to SpaceX for investors.

Analysis

The market is implicitly choosing between two very different duration trades: a cash-generative, de-risked franchise with identifiable reinvestment runway versus a capital-intensive, story-driven asset whose valuation depends on future milestones. That should keep a bid under LLY on any risk-off tape because it combines growth, buyback/dividend support, and pricing power; by contrast, SPCX is vulnerable to a multiple reset as soon as the post-IPO momentum fades and investors demand free-cash-flow visibility rather than TAM narratives.

Second-order, the real competitive pressure is not on the headline obesity market but on the access layer: if LLY keeps taking share and broadening into oral formats, payer negotiations become more favorable and weaker GLP-1 peers face either margin erosion or slower formulary wins. That dynamic is most damaging to companies with less manufacturing scale and less clinical breadth, because the winner can use supply reliability as a sales weapon while competitors are forced into discounting.

The main near-term catalyst is earnings/guidance credibility over the next 1-3 months; the structural catalyst is whether the oral pipeline converts into incremental, not cannibalized, demand over 6-18 months. Falsifiers are simple: a slowdown in prescription growth, adverse reimbursement commentary, or any safety/supply issue on the LLY side; for SPCX, a secondary offering, weaker-than-expected monetization, or a sharp rise in real yields would likely compress the valuation quickly. Consensus is probably underestimating how fragile a 100x-sales equity is when the market stops rewarding optionality and starts underwriting execution.

Key Decisions for Investors

• Relative value: long LLY / short SPCX into the next 1-3 months. The pair expresses quality vs. optionality; if market multiples stay disciplined, LLY should outperform while SPCX is exposed to post-IPO de-rating and any financing overhang.
• If outright long exposure is required, prefer LLY on pullbacks rather than chasing SPCX strength. Use earnings-season weakness as entry; the risk/reward is better because downside is anchored by cash flow and capital returns.
• For tighter risk control, buy LLY call spreads 3-6 months out instead of stock. This captures continued GLP-1 upside while limiting damage if the multiple compresses from already-elevated expectations.
• Set an alert on SPCX for lockup/secondary signals and any disclosure of slower near-term monetization. Those events would be the cleanest trigger to add to a short or reduce exposure.
• Watch NVO vs. LLY as the cleaner sector read-through. If LLY keeps taking share, prefer LLY over NVO; if payer pushback or supply constraints emerge, rotate out quickly because the multiple premium can compress fast.